US2008009603A1PendingUtilityA1

Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity

65
Assignee: UUTECH LTDPriority: Mar 29, 1999Filed: Jul 3, 2007Published: Jan 10, 2008
Est. expiryMar 29, 2019(expired)· nominal 20-yr term from priority
Inventors:Victor GaultFinbarr Paul Mary O'HarteNigel IrwinPeter Raymond Flatt
A61K 38/00C07K 14/575Y10T29/4935
65
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides peptide analogues which are antagonists of gastric inhibitory peptide (GIP). The peptides, based on GIP 1-42 include substitutions and/or modifications which have enhanced resistance to degradation by the enzyme dipeptidyl peptidase IV (DPP IV). The invention also provides a process of N terminally modifying GIP and the use of the peptide analogues for treatment of diabetes.

Claims

exact text as granted — not AI-modified
1 . A peptide analogue of GIP(1-42) (SEQ ID NO:1), comprising at least 12 amino acid residues from the N-terminal end of GIP(3-42).  
     
     
         2 - 38 . (canceled)

Join the waitlist — get patent alerts

Track US2008009603A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.